Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 4/20 | 0.40 |
| ▸ | HMGCR | P04035 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PDE6D | O43924 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220970 | 0.91 | GCGR (0.48) | GCGRHMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL4164340 | 0.85 | HMGCR (0.46) | GCGRHMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL17975734 | 0.84 | GCGR (0.53) | GCGRKIT | |
| SCHEMBL4907026 | 0.84 | HMGCR (0.46) | GCGRHMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL3082 | 0.84 | ADORA1 (0.45) | GCGRHMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL3264910 | 0.83 | GCGR (0.41) | GCGRKIT | |
| SCHEMBL4773885 | 0.83 | GCGR (0.41) | GCGRKIT | |
| SCHEMBL2218431 | 0.82 | GCGR (0.47) | GCGRHMGCRALDH1A1CYP3A4PDE6D | |
| SCHEMBL15139859 | 0.81 | GCGR (0.39) | GCGRKIT | |
| SCHEMBL5187531 | 0.81 | HMGCR (0.59) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653265-B2 | Preparation method of rosuvastatin calcium and its intermediates | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2014-02-18 | — | — | US | disclosed |
| US-20110124864-A1 | PREPARATION METHOD OF ROSUVASTATIN CALCIUM AND ITS INTERMEDIATES | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2011-05-26 | — | — | US | disclosed |
| US-20090124803-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | UNICHEM LABORATORIES LIMITED (IN) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124803-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN | ACSL5, HMGCR, PCSK9 | GCGR 1178/4885HMGCR 2/4885ALDH1A1 1776/4885 |
| US-20110124864-A1 | PREPARATION METHOD OF ROSUVASTATIN CALCIUM AND ITS INTERMEDIATES | CETP, HMGCR, MTTP | GCGR 2507/4885HMGCR 2/4885ALDH1A1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.